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Immunoglobulin replacement therapy (IGRT) has contributed critically to the management 
of primary antibody deficiencies (PAD) and the decrease in pneumonia rate. However, 
despite adequate IGRT and improved prognosis, patients with PAD continue to expe-
rience recurrent respiratory tract infections, leading to bronchiectasis and continuing 
decline in lung function with a severe impact on their quality of life. Moreover, non- 
infectious inflammatory and interstitial lung complications, such as granulomatous- 
lymphocytic interstitial lung disease, contribute substantially to the overall morbidity of 
PAD. These conditions develop much more often than appreciated and represent a 
major therapeutic challenge. Therefore, a regular assessment of the structural and func-
tional condition of the lung and the upper airways with appropriate treatment is required 
to minimize the deterioration of lung function. This work summarizes the knowledge on 
lung complications in PAD and discusses the currently available diagnostic tools and 
treatment options.
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iNTRODUCTiON
Immunoglobulin (Ig) replacement therapy (IGRT) has made a critical difference in the treatment 
of primary antibody deficiencies (PAD). Improvements in care have led to a decrease in severe 
bacterial infections, notably pneumonia. Since the introduction of modern IGRT in the 1980s, 
Ig doses have increased, resulting in significantly higher plasma IgG trough levels (Figure 1) (1). 
Abbreviations: BALF, bronchoalveolar lavage fluid; CF, cystic fibrosis; CI, confidence interval; COP, cryptogenic organizing 
pneumonia; COPD, chronic obstructive pulmonary disease; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte-
associated protein 4; CVID, common variable immunodeficiency; DLCO, diffusing capacity for carbon monoxide; DNase, 
recombinant human deoxyribonuclease (dornase alfa); DWI, diffusion weighted imaging; ESID, European Society for 
immunodeficiencies; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GLILD, granulomatous-lymphocytic 
interstitial lung disease; HRCT, high-resolution computed tomography; Ig, immunoglobulin; IGRT, immunoglobulin replace-
ment therapy; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin G; KMT2D, lysine methyltransferase 2D; LCI, 
lung clearance index; LDCT, low-dose computed tomography; LIP, lymphocytic interstitial pneumonitis; LRBA, lipopolysac-
charide responsive beige-like anchor protein; MBIR, model-based iterative reconstruction; MBW, multiple breath washout 
technique; MDA5, melanoma differentiation-associated protein 5; MRI, magnetic resonance imaging; PAD, primary antibody 
deficiencies; PET, positron emission tomography; RAG1, recombinase-activating gene 1; TACI, transmembrane activator and 
calcium-modulator and cyclophilin ligand interactor; VATS, video-assisted thoracoscopic surgery; XIAP, X-linked inhibitor of 
apoptosis protein; XLA, X-linked agammaglobulinemia.
FiGURe 1 | Development of immunoglobulin replacement therapy and infection rates since 1990s. Data for immunoglobulin (Ig) trough levels (top left) and infection 
rates (top right) are from a cohort of 115 patients with common variable immunodeficiency (CVID) or X-linked agammaglobulinemia reported by Lucas et al. (1).  
A combined analysis of data on the percentage of patients experiencing pneumonia and recurrent respiratory tract infections (bottom left) is shown in three large 
series of CVID patients in 1999, 2008, and 2011 (two from the same cohort in the United States 12 years apart, 248 and 252 patients, and one from a French 
cohort, 473 patients); reproduced with kind permission from 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 67–69 (2). Mortality 
data (bottom right) for 1971 are from Healy et al. (6); those for 1999 and 2012 are from a single cohort follow up reported by Resnick et al. (7). DEFI, a French 
national study. Abbreviation: PAD, primary antibody deficiencies.
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The incidence of bacterial pneumonia in patients with PAD has 
been nearly halved (2) and the major risk factors—low IgA levels, 
combination of low IgA and IgM levels (3, 4), low IgG levels 
despite replacement IGRT, chronic sinusitis, bronchiectasis, 
and low number of class-switched memory B cells—are known, 
directing risk stratification, informing monitoring, and detecting 
early symptoms. Over a period of 40 years, the mortality rate in 
patients with common variable immunodeficiency (CVID) has 
decreased steadily from 29% in 1971 [before the introduction of 
intravenous IgG (IVIG)] to 24% in 1999 and 19.6% in 2012 (5–7). 
An analysis of the European Society for Immunodeficiencies 
(ESID) registry data provided an overall mortality estimate 
of 15%, with 75th and 60th percentiles for survival of 25 and 
41  years after diagnosis [95% confidence intervals (CI) 22–33 
and 33–41 years, respectively] (8).
However, despite improved therapy and prognosis, patients 
with PAD continue to experience non-infectious chronic lung 
disease and recurrent respiratory tract infections even with 
adequate IGRT (i.e., IGRT that raises trough IgG levels to within 
the range of healthy individuals), leading to an ongoing decline 
in lung function—in fact, the decline is greater than that in heavy 
smokers (9, 10). Pulmonary complications are common in a wide 
range of PAD and have a severe impact on patients’ quality of life 
(11–13). At the time of diagnosis, most patients have already suf-
fered from recurrent bacterial pulmonary infections, leading to 
bronchiectasis and/or obstructive lung disease in some patients. 
Additionally, non-infectious complications are an increasing 
cause of morbidity and mortality in PAD. For example, structural 
and functional lung impairment is now recognized as an impor-
tant risk factor for early mortality in CVID (7). In fact, these 
non-infectious complications—caused by immune dysregulation 
and not limited to the lung—have emerged as a major diagnostic 
and therapeutic challenge.
Therefore, active and accurate screening is mandatory even in 
“well-controlled” patients, but the absence of structured protocols 
for follow-up is a major challenge toward identifying and treating 
lung complications (14). This review focuses on the current chal-
lenges in the management of lung disease in patients with PAD.
iMMUNiTY AND iMMUNODeFiCieNCY  
OF THe ReSPiRATORY SYSTeM
The lung is an organ of enormous surface area combined with 
delicate structure that encounters a large amount and variety of 
pathogens capable of causing infection. Igs play a major role in 
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the protection of the lung against infection, with specific roles 
for different isotypes (15). Different Ig isotypes are dominant in 
different parts of the lung in the airways: the respiratory surface 
in the upper and lower airways is covered predominantly with 
secretory IgA (sIgA) and IgM, while in the alveolar space, IgG is 
the dominant isotype (16, 17).
Both sIgA and IgM at the bronchial surface mostly derive from 
the mucosa associated lymphatic tissue, rather than from the 
systemic circulation (15, 18, 19). sIgA prevents bacterial adhesion 
or neutralizes toxins without causing an inflammatory response, 
in contrast to IgG and monomeric IgA (20). IgM activates the 
complement system, which enhances opsonization of pathogens. 
Due to its multimeric structure, IgM is highly effective for 
agglutination, especially of viruses (20). Alveolar IgG originates 
from the systemic circulation by passive diffusion and effectively 
prevents bacterial infections such as pneumonia (19, 21).
In most patients with PAD, both systemic IgG and local IgA 
are absent or dysfunctional; indeed, one of the criteria in the defi-
nition of CVID in the revised ESID and International Consensus 
guidelines is low IgA and/or low IgM (22, 23). sIgA seems to play 
a negligible role for airway defense because individuals with 
selective IgA deficiency are commonly healthy. However, the 
observation that patients with CVID suffer from airway infections 
more severely with very low IgA levels (i.e., less than 0.07 g/L) 
compared with those with higher IgA levels (24) argues that IgA 
can compensate for IgG deficiency in airway defense, at least in 
part. Combined deficiency of IgA and IgM seems to be even more 
detrimental if IgG is lacking (25) suggesting that IgM is also a 
cofactor for airway defense.
Without IGRT, the most common infection sites in patients 
with X-linked agammaglobulinemia (XLA) and CVID are in the 
airways (2, 26, 27). The same types of bacteria reside in the upper 
and lower airways in PAD, with analogous evidence in the set-
ting of cystic fibrosis (CF) for Pseudomonas aeruginosa (28). The 
concept that the upper airways form a gateway and a reservoir 
of infection for the lower airways was supported by the same 
genetic fingerprint bacteria collected from nasal and bronchial 
simultaneously (29). Therefore, the optimal pulmonary manage-
ment of patients with PAD must encompass the upper airway, the 
“gateway to the lungs.”
ReSPiRATORY iNFeCTiONS iN PAD: 
wHAT iS BeiNG MiSSeD
The different and only partially overlapping physiological roles 
and locations of IgG, IgA, and IgM suggest that there are sev-
eral defects in the defense of the airways, only one of which is 
addressed by current IGRT. This helps to explain why patients 
with PAD experience recurrent respiratory tract infections even 
with regular IGRT. The most common infections are sinusitis and 
upper respiratory tract infections, but the range is much broader 
and not limited to the lungs (Figure 2).
Encapsulated bacteria such as Haemophilus influenzae, Strep­
tococcus pneumonia, and Moraxella catarrhalis are the most 
common causative agents of recurrent infections. However, non- 
encapsulated, non-typeable strains of these bacteria have been 
identified as an important cause of pneumonia, sinusitis, bron-
chitis, and otitis in this patient population (30). Rhinovirus is 
another frequent causative agent of recurrent infections that 
leads to prolonged airway infection and inflammation in patients 
with hypogammaglobulinemia (31). Viral infection may render 
the airway mucosa susceptible for new bacterial infection (32) or 
aggravate bacterial infection as shown in patients with CF (33). 
In chronic obstructive pulmonary disease (COPD), rhinoviral 
infection exacerbates the existing microbiome with outgrowth 
of particular bacteria (34). P. aeruginosa should always be sought 
particularly where there is an evidence of structural damage 
(26). Also, Mycoplasma spp infections seem to play a role in 
pulmonary and non-pulmonary disease in patients with PAD 
(35–38).
Subclinical infections
Subclinical infections are well documented in patients with PAD, 
and a number of bacteria and viruses can be identified even in 
the periods when patients have no evident active infection. For 
example, a study of patient bronchoalveolar lavage fluid (BALF) 
detected bacteria in the lower respiratory tract of 9/14 asymp-
tomatic patients, 6 of whom harbored erythromycin-resistant 
strains of H. influenzae (26). Adenoviruses were found in 4/14 
patients; 2 of these patients had a dual infection with both adeno-
virus and rhinovirus (26). Similarly, a 12-month follow up study 
in 12 patients with PAD demonstrated the presence of respiratory 
viruses, most commonly rhinovirus, in the sputum in half of the 
65 acute infection episodes (27). Moreover, virus elimination was 
much longer in patients with PAD than in healthy individuals. 
Rhinovirus shedding in patients with PAD lasted on average 
40.9 days (95% CI: 26.4–55.4 days) compared to 11.4 (8.2–14.7) 
days and 10.1 (7.4–12.9) days in immunocompetent children 
and adults, respectively (27, 31). Not only did respiratory tract 
symptoms persist for the duration of virus shedding, but also new 
infections by another rhinovirus type appeared often soon after 
the first episode (31).
In the long term, recurrent infections often lead to lung dam-
age and chronic lung disease, with bronchiectasis being the most 
common complication. Studies with long follow up (up to 11 years) 
have shown that a substantial proportion of patients present 
with chronic lung disease at the time of diagnosis or develop it 
despite IGRT maintaining IgG levels to within the normal range 
(24, 39, 40) (Figure 3). The cumulative risk of chronic lung disease 
increases with disease duration and is not dependent on the age at 
diagnosis (39, 40). The rate of lung decline in PAD is much faster 
than that predicted in healthy individuals: the average decline of 
forced expiratory volume in 1 s (FEV1) in patients with CVID or 
XLA [45 mL/year (9)] is not only more than twofold higher than the 
normal age-related decline in healthy non-smoking individuals 
[19.6 and 17.6 mL/year for males and females, respectively (10)], 
but also higher than the decline in continuous smokers [38.2 and 
23.9 mL/year in males and females, respectively (10)]. Even in 
one IVIG cycle, infections appear more frequently at the end of 
the cycle when trough Ig levels are low. A recent study showed 
that the risk ratio of a new infection was higher in the last com-
pared to the first week of the IVIG cycle (1.55 for a 4-week cycle; 
P = 0.0314) (41). Therefore, it is likely that the optimization of 
FiGURe 3 | Prevalence of chronic lung disease before and during 
immunoglobulin replacement therapy (IGRT). Prevalence before and during 
IGRT is shown. Data for chronic lung disease are from Plebani et al. (XLA) 
(39) and Quinti et al. (CVID) (40). Abbreviations: CVID, common variable 
immunodeficiency; XLA, X-linked agammaglobulinemia.
FiGURe 2 | Infectious and non-infectious complications in primary antibody deficiencies. Abbreviations: GLILD, granulomatous-lymphocytic interstitial lung disease; 
IgA, immunoglobulin A; LIP, lymphocytic interstitial pneumonitis.
4
Baumann et al. The Lung in Primary Immunodeficiencies
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1837
trough IgG levels by increasing the total dose or shortening the 
interval will limit this difference in risk of infection. The stable 
IgG levels achieved using SCIG would also be expected to limit 
this in-dosing cycle variation.
Bronchiectasis
Bronchiectasis is the irreversible scarring of the lung tissue result-
ing from infection and the ensuing inflammatory response 
(Figure  4A). Inflammation leads to excess mucus production 
and impaired mucociliary clearance, the latter in turn contrib-
utes to the increased number of bacteria residing in the lung, 
leading to a vicious cycle of inflammation and infection (42, 43). 
If inflammation lasts long enough or is severe enough, it leads 
to irreversible ulceration of the tissue with the involvement of 
fibroblasts and to scaring (44). Similar to other lung complica-
tions, bronchiectasis may develop despite regular IGRT (40). 
Morphologically, there are three types of bronchiectasis that 
reflect increasing severity of bronchial disease and its progression 
FiGURe 4 | Morphology and prevalence of bronchiectasis. (A) Schematic presentation of normal bronchi and bronchi with bronchiectasis. The upper airways (blue) 
are more exposed to pathogens compared with the lower airways (orange). (B) Types of bronchiectasis. (C) Prevalence of bronchiectasis before and during IGRT. 
Data are from Quinti et al. (24).
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to the more central airways: cylindrical (also called tubular), 
varicose, and cystic (45, 46) (Figure  4B). The key symptoms 
of bronchiectasis are prolonged cough, excessive production 
of sputum, shortness of breath and wheezing, and chest pain. 
Severe and/or widespread bronchiectasis can lead to respiratory 
failure, atelectasis, and heart failure. Diagnosis of bronchiectasis 
is not straightforward and requires chest tomography imaging 
by either computed tomography (CT) or magnetic resonance 
tomography. Conventional chest X-ray imaging detects only a 
third of bronchiectatic lesions (47).
The prevalence of bronchiectasis among patients with PAD 
rises with age regardless of IGRT (Figure  4C). Over a 5-year 
observation period, the prevalence of bronchiectasis in patients 
with CVID increased from 47.3 to 53.7%, with age and serum 
IgA levels lower than 0.07  g/L being independent risk factors 
(24). Also in patients with XLA, the prevalence of bronchiectasis 
increased from 33 to 39% (24). The prevalence of chronic sinusitis 
increased with age in CVID and XLA patients, too, with low IgA 
serum levels being an independent risk factor in CVID (24, 39, 40). 
Moreover, because prevalence of chronic sinusitis was higher 
than prevalence of bronchiectasis in both patient cohorts, it is 
likely that bronchiectasis may develop late in the course of a 
common airway disease in PAD as a result of a chronic bacte-
rial infection commencing in the upper airways, or as a sequel 
of prolonged inflammation, or both. Etiology of bronchiectasis 
may differ between CVID patients, as suggested by an increasing 
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number of conditions with immune dysregulation rather than 
immunodeficiency. According to our own preliminary data in a 
large cohort of pediatric and adult CVID patients, IGRT does not 
appear to ameliorate the course of lung disease; the prevalence 
of bronchiectasis rises no less after establishing IGRT than with 
duration of disease.
Because the scarring of the lung tissue is irreversible, treat-
ment of bronchiectasis focuses on preventing further tissue dam-
age and alleviating the consequences. Treating the primary cause 
of bronchiectasis and reducing the risk of recurrent infections 
by optimization of IGRT and use of prophylactic antibiotics to 
stop the vicious cycle of inflammation are the primary goals. In 
addition, medication helping bronchodilation, mucus thinning, 
and expectoration can provide relief.
New Therapeutic Approaches
New preventive and therapeutic approaches are urgently needed 
to alleviate lung damage in patients with PAD. Several potential 
treatments, including oral or inhaled antibiotics, inhaled hyper-
osmolar agents, mucolytic agents, airway clearance techniques, 
nasal irrigation, or nasal drug deposition have been tested in 
various settings associated with bronchiectasis (48). However, 
there are yet no published clinical trial results documenting their 
efficacy and safety in PAD.
Nasal irrigation and drug deposition in the nose or sinuses 
is a logical choice for delivering medication in patients with 
PAD similarly to immunocompetent individuals. The paranasal 
sinuses are poorly ventilated and often harbor chronic infections 
as in chronic sinusitis. Improving the sinus clearance may reduce 
the risk of infection in the lower airways. However, despite the 
fact that aerosolized drugs have been used for a long time, effi-
cient drug delivery to the posterior nose and paranasal sinuses is 
still a challenge, because most aerosolized drugs are filtered by 
their passage through the nose (49). Irrigation of the nose using 
large-volume squeeze bottles has been shown to be effective (50), 
whereas nasal pump sprays could not deliver the aerosol to the 
sinuses (51). Pulsating aerosol delivery systems use a pulsating 
airflow to ventilate the sinuses and introduce the aerosolized 
medication (e.g., antibiotics and mucolytic agents) into the para-
nasal sinuses, which otherwise would be inaccessible (49). Studies 
using a paranasal nebulizer have shown that up to 6.5% of the 
nasally deposited drug was found in the sinuses (51). In addition, 
compared with nasal pump sprays, retention kinetics of the drug 
deposit in the nose was prolonged threefold (49, 52). This method 
can be used to deliver topical antibiotics, hyperosmolar agents, or 
even Ig directly in the airways or the lungs (53). In CF, applica-
tion of tobramycin and recombinant human deoxyribonuclease 
(DNAse, Dornase alfa, Genentech, Inc., San Francisco, CA, USA) 
to the paranasal sinuses by oscillating pulse wave nebulization 
has proven beneficial for reduction of bacterial load and clinical 
symptoms (54, 55).
Antiviral treatment may be beneficial in patients who suffer 
from recurrent viral respiratory infections despite adequate 
IGRT. Preliminary studies in patients with PAD suggest that 
antiviral agents, such as nebulized ribavirin and pegylated inter-
feron can reduce replication of rhinovirus at the airway site and 
improve symptoms (56). Patients with PAD do not appear to be 
prone to all viruses equally. Respiratory syncytial virus, which 
affects virtually all infants before they mount a specific immune 
response, does not appear to be a frequent pathogen in patients 
with PAD beyond infancy (57); this argues that IGRT affords 
protection against this respiratory pathogen. It is surprising that 
influenza infection, which regularly causes epidemics in the 
healthy population, has not received major interest in studies of 
PAD (57). Passive immunization by IGRT is likely to afford only 
limited protection against influenza, for donors (whose blood has 
been used to manufacture Ig products) have not been immunized 
against the most recent influenza strains. Moreover, active immu-
nization of CVID patients induces only a weak, if any, antibody 
response (58). However, T-cell mediated immunity may respond 
better to influenza vaccination, supporting the common recom-
mendation to immunize all patients with PAD (59). Recently, 
the first case of melanoma differentiation-associated protein 5 
deficiency was reported in a patient with PAD; this inborn error 
resulted in susceptibility specifically to rhinovirus infection (60). 
Antiviral treatment might be useful in patients who suffer from 
recurrent viral respiratory infections despite adequate IGRT. 
Unfortunately, antiviral agents are not routinely available to treat 
all viral infections, including rhinovirus infection, and even if any 
were available there might be a risk of resistance with repeated or 
prolonged use.
In the past several years, research of the immune mecha-
nisms controlling the susceptibility to chronic bacterial infection 
focused increasingly on the lung microbiota as a major factor 
informing and calibrating the immune system. The topic of the 
interaction of the microbiota with the host immune system is 
outside the scope of this work, and there are several excellent 
reviews summarizing the research to date (61–63). The “disap-
pearing microbiota hypothesis” proposed by Blaser and Falkow 
offers an explanation for the increased burden of inflammatory 
disease as a result of changing hygiene, human macroecology, 
and clinical practice (64). The lung is a complex microbial eco-
system, in which different pathogens compete for survival not 
only with one another but also with the commensal microbiota 
(62). Animal studies have shown that not all members of the 
microbiota have an equal ability to influence the immune system, 
thus the disruption of the microbiota composition may result 
in a reduced host defense against bacterial and viral infection 
(65–67). Also, studies have shown that microbiota-depleted mice 
had significant loads of bacteria and viruses compared with mice 
with normal microbiota. In humans, the lung microbiota differs 
between health and inflammation, whereby in the latter situation 
the broad range of microbiota is substantially reduced, appearing 
“missing” or “simplified” (62, 64, 68). For example, subjects with 
asthma or COPD have a distinctive lung microbiota composition 
compared to healthy controls (69, 70). In patients with CVID, 
inflammatory complications are associated with reduced within-
individual bacterial diversity, and dysbiosis (i.e., an unhealthy 
imbalance in the normal bacterial ecology), and elevated immune 
cell activation markers in the gut (71). Evaluating the pulmonary 
microbiome may evolve as a new diagnostic tool to assess the 
risk of progression of lung disease. Active modification of the 
pulmonary microbiome in patients with PAD may reduce 
ecological niches for pathogens and have a beneficial effect on 
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host defense even with an immune system that functions only in 
part. Although research of the lung microbiota lags substantially 
behind that of the gut microbiota, modifying (or restoring) the 
microbiota of the airway mucosa using probiotics, similar to the 
approach used in the gut, may help in maintaining a favorable 
immunological balance (63).
Adjunctive Therapies
The recently completed first study on antibiotic prophylaxis in 
Italian patients with PAD evaluated the efficacy and safety of low 
doses of azithromycin (250  mg three times per week on three 
consecutive days) for 24 months vs placebo (72). The results of 
this study will provide much needed evidence of the efficacy of 
antibiotic prophylaxis. Regarding the practice of antibiotic usage 
for the treatment of respiratory infections, a recent prospective 
study reported that patients delay antibiotic treatment by a 
median of 5 days until they suffer specific “warning” symptoms, 
such as cough, shortness of breath, and purulent sputum (73). As 
the authors of this article point out, this finding is unexpected, 
as patients should have access to antibiotics for immediate use 
and are advised to start treatment when they have a breakthrough 
infection. Whether this delay is a matter of patient choice or of 
access to healthcare remains to be investigated. In addition, only 
exacerbations characterized by purulent sputum appeared to 
respond to use of antibiotics, while exacerbations with signs of 
upper respiratory tract infections did not. Moreover, exacerba-
tions were as frequent in patients using prophylactic antibiotics, as 
in those using antibiotics on demand. It remains unclear whether 
the outcomes would have been different if antibiotic treatment 
was commenced earlier than 5  days after onset of symptoms. 
Finally, respiratory viruses were detected more frequently than 
bacterial pathogens. These findings argue for a careful evaluation 
of the causing pathogen as guidance for the use of antibiotics.
Hyperosmolar agents, most commonly hypertonic saline, have 
been used to break the vicious cycle of mucus retention and infec-
tion in patients with bronchiectasis (74). Another approach to 
improve mucus elimination is using mucolytic agents (carbocyst-
eine orally or nebulized DNAse) to increase mucus fluidity and 
facilitate expectoration and, while this approach has been used 
in selected PAD patients, there are no controlled studies in PAD. 
The observation that DNAse improves lung function parameters 
(FEV1) in patients with CF (75), while it leads to FEV1 deteriora-
tion in patients with non-CF bronchiectasis (76), indicates that 
the efficacy of therapeutic interventions may differ substantially 
between various pulmonary conditions. Therapeutic strategies, 
therefore, need to be carefully assessed in controlled clinical trials 
in patients with PAD.
NON-iNFeCTiOUS PULMONARY 
COMPLiCATiON iN PAD
Non-infectious pulmonary complications in PAD are common 
and contribute substantially to morbidity. Thus, in CVID, two 
independent studies have shown that patients with disease-
related non-infectious complications have a significantly poorer 
survival prognosis than those without complications: the risk of 
death was estimated to be 11-fold higher than that in patients 
with infections only (P <  0.001) (7, 8). Approximately 30% of 
patients with CVID have diffuse interstitial lung disease (ILD) 
(51). Etiology is unknown in most cases, but multiple monogenic 
causes have been identified (77).
Non-infectious pulmonary complications include different 
forms of ILD, such as granulomatous-lymphocytic ILD (GLILD), 
cryptogenic organizing pneumonia (COP), lymphocytic inter-
stitial pneumonitis (LIP), follicular bronchiolitis (FB), and/or 
lymphoid hyperplasia. Screening with high-resolution computed 
tomography (HRCT) chest scan indicates a much higher per-
centage of patients with ILD and bronchiectasis among those 
with PAD than previously appreciated (78). Establishing a cor-
rect pathological diagnosis is crucial for treatment of ILD. For 
instance, COP is responsive to steroids, whereas in GLILD, other 
treatments may be needed.
Granulomatous-Lymphocytic iLD
Granulomatous-lymphocytic ILD is the pulmonary component 
of a non-necrotizing, systemic disease characterized by adenopa-
thy, splenomegaly, and granulomatous inflammation that may 
affect not only the lung, but also the liver, bone marrow, and 
lymph nodes (79, 80). The prevalence of GLILD in patients with 
PAD is unknown; however, it is found in CVID and an increasing 
number of monogenic disorders. Approximately 20% of patients 
with GLILD present with polyclonal lymphocytic infiltration 
or nonmalignant hyperplasia of the lymph nodes in addition 
to granuloma (80). GLILD typically occurs in the context of 
CVID; so far, GLILD has not been described in congenital 
agammaglobulinemia.
The key histopathological features of GLILD are LIP, FB, and 
non-necrotizing granuloma (Table  1; Figure  5). These histo-
pathological features are numerically more frequent in the lower 
lung zones and are found in the same biopsy in nearly all patients. 
LIP often manifests as a mix of moderate to severe peribronchiolar 
and interstitial lymphoid infiltration. The predominant cells in 
the infiltrate are CD4+ T cells, but nodules of CD20+ B cells sur-
rounded by CD4+ T cells are also found, predominantly localized 
to the interstitium (81). Distinct B-cell follicles and T-cell areas 
have been observed also in patients with CVID and lymphoid 
hyperplasia (82). Surprisingly, regulatory T  cells are absent in 
the lungs in GLILD (81). This latter observation is in agreement 
with previous reports indicating reduced numbers and function 
of regulatory T cells in blood in CVID associated with GLILD 
(83–86). Granulomas are non-necrotizing, poorly to well-formed, 
and widely distributed, but with lower lung zone predominance, 
occasionally in association with interstitial inflammation (81).
In addition to LIP, FB, and granuloma, organizing pneumonia 
and interstitial fibrosis are also found in most patients with GLILD 
and are moderate or severe in approximately half of the cases (81). 
Organizing pneumonia is characterized by Masson bodies amidst 
pale, myxoid stroma within the alveoli and adjacent interstitium. 
Interstitial fibrosis is characterized by areas of collagenized fibro-
sis, with the more severe cases being accompanied by alveolar 
remodeling (81). Whether GLILD causes progressive pulmonary 
fibrosis is somewhat controversial. However, moderate to severe 
FiGURe 6 | Granulomatous-lymphocytic interstitial lung disease diagnostic 
algorithm. All patients with common variable immunodeficiency should have 
a high-resolution computed tomography (HRCT) of the chest to screen for 
pulmonary disease. If there is significant interstitial lung disease (ground glass 
abnormalities, nodules, and areas of consolidation), one should consider  
lung biopsy by video-assisted thoracoscopic surgery (VATS) for definitive 
diagnosis. It may be worth considering if a more easily accessible organ  
such as a lymph node could be useful for detection of granulomas.
FiGURe 5 | Histologic features of granulomatous-lymphocytic interstitial lung disease. (A) Lymphocytic interstitial pneumonitis. Diffuse, lymphocytic interstitial 
infiltrates obliterating the alveolar spaces in some areas (100×). (B) Follicular bronchiolitis. Nodular, lymphoid peribronchiolar aggregates (100×). (C) Non-necrotizing 
granuloma with multinucleated giant cells (arrow; 200×). Hematoxylin and eosin staining.
TABLe 1 | Histopathological features of GLILD.
Featurea Occurrence (N = 16) Severity Key features
Lymphocytic interstitial pneumonitis 100% Mild 19% Lymphocytic infiltration of variable density—peribronchiolar and interstitial
Moderate 25%
Severe 56%
Follicular bronchiolitis 100% Mild 25% Consistently present; nodular peribronchial inflammation associated  
with interstitial inflammationModerate 56%
Severe 19%
Non-necrotizing granuloma 93.75% (15/16 cases) Mild 50% Well, moderate, or poorly circumscribed; non-necrotizing, may be cuffed by 
lymphocytes or associated with lymphoid infiltration; random distributionModerate 31.25%
Severe 12.5%
Organizing pneumonia 87.5% (14/16 cases) Mild 43.75% Variable severity with Masson bodies and other typical features of COP
Moderate 37.5%
Severe 6.25%
Interstitial fibrosis 75% (12/16 cases) Mild 31.25% Variable severity from patchy to extensive areas of collagenized fibrosis
Moderate 25%
Severe 18.75%
aData from Rao et al. (81).
COP, cryptogenic organizing pneumonia; GLILD, granulomatous-lymphocytic interstitial lung disease.
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pulmonary fibrosis has been found in 44% of patients with 
GLILD strongly suggesting this leads to progressive pulmonary 
fibrosis (78, 87, 88). However, the presence of moderate to severe 
interstitial fibrosis in the lung biopsies of nearly 50% of patients 
with GLILD strongly argues this is a progressive lung disease in 
most patients.
Suspicion for GLILD should be raised particularly with the 
presence of lymphadenopathy, splenomegaly, autoimmunity, or 
a low number of class switched memory B-cells. Diagnosis of 
GLILD is based on HRCT of the chest (Figure 6) and, possibly, 
lung biopsy. Typical radiographic features of GLILD include 
large nodules and small nodules, areas of consolidation, and 
ground glass abnormality predominantly located in the lower 
lung zone, and frequent mediastinal adenopathy. The differential 
diagnosis of diffuse parenchymal disease in patients with CVID 
is extensive and includes LIP, nonspecific interstitial pneumo-
nia, usual interstitial pneumonia, sarcoidosis, hypersensitivity 
pneumonitis, COP, low- and high-grade lymphoma, GLILD, as 
well as infection. To make a definitive diagnosis in a patient 
with suspected GLILD, we (JR) recommend a biopsy via video-
assisted thoracoscopic surgery (VATS) with sampling of at least 
two lobes of the lung. Several studies have demonstrated that 
FiGURe 7 | Diagnosis of granulomatous-lymphocytic interstitial lung disease (GLILD). (A) PET-CT before and 3 months after rituximab and mycophenolate 
treatment. Whole body images were acquired at 90 min following 285 MBq 2-[(18)F]-fluoro-2-deoxy-d-glucose (tracer). Maximum intensity projection whole body 
images before treatment show widespread abnormal uptake of tracer in the lung parenchyma and lymph nodes above and below the diaphragm (A); images 
following treatment show near resolution of all the areas of abnormal tracer uptake (B). (C,D) Axial fused positron emission tomography–computed tomography 
(PET–CT) images at the mid-thoracic level. The level of tracer uptake is represented by the intensity of color superimposed upon the CT image. There is a 
combination of interstitial septal thickening and ill-defined tracer-avid peri-bronchovascular nodules before treatment (C); post-treatment image shows improvement 
of the nodularity with near resolution of tracer uptake (D). Images at the level of the carina show an enlarged lymph node exhibiting intense abnormal tracer uptake 
prior to treatment (E), and a normalized lymph node with no abnormal tracer uptake following treatment (F). Pre-treatment images through the abdomen at the level 
of the right renal hilum demonstrate numerous enlarged tracer-avid retroperitoneal lymph nodes (G) which reduce in size and tracer uptake following treatment (H). 
Reproduced with kind permission from 2016 British Society for Immunology, Clinical and Experimental Immunology, 187: 138–145 (100). (B) Radiographic features 
of GLILD versus sarcoidosis. GLILD is characterized by macronodular (yellow circles) disease that is located predominantly in the lower lung zones. In contrast, 
micronodular (yellow circles) disease located in the upper lung zones and frequently accompanied by marked hilar adenopathy (stars) is characteristic of sarcoidosis. 
Reproduced from Ref. (101) with kind permission from European Respiratory Society.
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VATS is superior to transbronchial biopsy in determining a defi-
nite diagnosis in cases of suspected ILD (89–94). As previously 
mentioned, most patients with GLILD have significant areas of 
organizing pneumonia. Therefore, a transbronchial biopsy may 
lead to the misdiagnosis of COP due to sampling artifact. 
Simi larly, transbronchial biopsy may yield insufficient tissue 
to make the diagnosis of lymphoma, particularly low-grade 
lymphoma. VATS also provides additional prognostic (extent of 
fibrosis) and diagnostic (e.g., B-cell lymphoma of low or high 
grade) information that may not be obtained by transbronchial 
biopsy. The 30-day post-operative mortality rate is 0–6% (89–93, 
95, 96), which varies according to the clinical status of the 
patient as well as the expertise present in a given center (91, 
92, 95, 97). Complications include pneumothorax, pulmonary 
atelectasis, lower respiratory tract infections, poor lung expan-
sion, and more rarely (<5%) surgical emphysema, prolonged 
neuropathic pain, delayed wound healing, persistent air leak, 
acute respiratory distress, and hemothorax (91, 92, 95, 97). 
In children, VATS is recommended only if the diagnosis is 
uncertain despite thorough clinical evaluation or therapeutic 
decisions cannot be made without histology (98, 99). Positron 
emission tomography (PET) with 2-[(18)F]-fluoro-2-deoxy-d-
glucose (FDG) combined with CT allows identification of active 
lymphoproliferative sites early in the inflammatory process and 
shows the systemic nature of the condition (Figure 7A) (100). 
In addition, FDG PET-CT shows sites of lymphoproliferation 
that may be more amenable for biopsy and confirmation of 
granulomatous inflammation than the lung. An additional 
alternative approach for confirming granulomatous histology 
would be using the tissue obtained at splenectomy if this had 
been undertaken. Obtaining tissue from more accessible organs 
should also be considered. For example, a skin biopsy can help 
to confirm or exclude sarcoidosis.
While there is no universally accepted diagnostic process for 
GLILD, decisions are made individually and further studies will 
be needed to define the optimal approach.
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Differentiating between GLILD and sarcoidosis can be poten-
tially challenging, owing to the systemic nature of both disorders 
and the somewhat similar pathological findings (80). While both 
sarcoidosis and GLILD have non-necrotizing granuloma, FB and 
LIP are much more prominent in GLILD. Radiographically, the 
abnormalities in sarcoidosis are predominantly in the upper lung 
zones and consist of micronodular disease and a pronounced 
hilar adenopathy, whereas GLILD is characterized by micro-
nodular and macronodular disease, diffuse adenopathy with less 
prominent hilar adenopathy, and lower lung zone predominance 
(Figure  7B). Bronchiectasis is uncommon in sarcoidosis, but 
occurs in 20–50% of patients with GLILD. In addition, plasma 
cells are present in the lung in sarcoidosis, but not in GLILD, 
consistent with the general absence of plasma cells in GLILD 
and CVID.
Monogenic disorders causing CVID-like diseases have now 
been well described in patients with GLILD: mutations in the 
transmembrane activator and calcium-modulator and cyclophi-
lin ligand interactor (TACI), cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) haploinsufficiency (102), lipopolysaccharide 
responsive beige-like anchor protein (LRBA) deficiency (103), 
mutations in the X-linked inhibitor of apoptosis protein (XIAP), 
hypomorphic recombinase-activating gene 1 (RAG1) mutations 
(104, 105), and lysine methyltransferase 2D (KMT2D) mutations 
(106). Patients with enteropathy, immune cytopenias, or other 
autoimmune or central nervous system diseases should raise 
the suspicion of LRBA deficiency or CTLA4 haploinsufficiency. 
Overall, 66% of patients with CTLA-4 deficiency were found to 
have GLILD (107, 108). LRBA functions to maintain the intracel-
lular stores of CTLA-4 (109), and, therefore, LRBA deficiency and 
CTLA-4 deficiency have a similar clinical phenotype. The question 
whether all CVID patients should undergo at least targeted DNA 
sequencing remains to be answered (110–112). Determining the 
genetic cause of CVID might result in a change of treatment of 
various complications and improve prognosis. However, patients 
with a severe inflammatory/autoimmune disease, early presenta-
tion (younger than 10 years), multiple affected family members 
or very low numbers of B cells may have a higher likelihood of 
identification of a causative gene using next-generation sequenc-
ing approaches (112).
There are no guidelines and few reports on treatment of 
GLILD. However, the presence of both B and T  cells in the 
infiltrate suggests a combination immunosuppressive therapy 
targeting both cell populations might be beneficial. Indeed, a com-
bination of rituximab and azathioprine improved radiographic 
abnormalities and pulmonary functional tests (PFTs) in seven 
patients with CVID and GLILD (113). Rituximab (375 mg/m2/ 
week) is administered intravenously once a week for 4 weeks, and 
this course is repeated 3–4 times at 4–6-month intervals. Oral 
azathioprine is given concomitantly for 18 months. In patients 
with poor tolerability for azathioprine, its active metabolite, 
6-mercaptopurine, can be used. If the patient does not tolerate 
either of these drugs, mycophenolate mofetil is also effective. 
The dosage of these immunosuppressants needs to be adjusted to 
maintain an adequate lymphocyte and neutrophil count. Other 
immunosuppressive medications that have been reported to 
have a beneficial effect in GLILD include abatacept in patients 
with LRBA or CTLA4 haploinsufficiency (109, 114), tumor 
necrosis factor-α inhibitors (115), and corticosteroids (116). In our 
experience, corticosteroids do not lead to a durable remission. 
A double-blind placebo-controlled trial is needed to define the 
natural history of GLILD and document efficacy of immunosup-
pressive approaches in GLILD.
ASSeSSMeNT OF THe LUNG iN PAD
Pulmonary Function Tests
Pulmonary function tests provide useful information on lung 
performance and on the extent and progression of chronic lung 
disease in patients with PAD, in addition to the overall clinical 
assessment and physical examination. The most commonly 
performed PFT is spirometry providing data on the forced vital 
capacity (FVC) and FEV1: abnormal FVC and FEV1 readings 
may indicate restrictive and obstructive lung disease, respectively. 
In patients with PAD, decline in FEV1 has been shown to be a 
more sensitive indicator of respiratory function than FVC, as 
expected due to the obstructive nature of bronchiectasis (117). 
In addition to assessments performed by spirometry, regular 
assessment of diffusing capacity for carbon monoxide (DLCO) in 
suspected ILD is useful alone (117). This is one of the reasons why 
care of CVID patients should be managed by specialized centers 
that have access to other specialties, including a pulmonology 
liaison service. DLCO should also be evaluated in all patients with 
splenomegaly and/or lymphadenopathy.
In a study of 37 patients with CVID and XLA, the average 
annual decline in FEV1 was 45 ± 6 mL/year (9), which exceeds 
the normal rate of decline of 19.6 and 17.6 mL/year in healthy 
non-smoking males and females, respectively (10). In this 
study, lung function decline correlated inversely with IVIG dose 
(P =  0.004), indicating that higher IVIG doses are associated 
with preservation of lung function, although the correlation 
between trough IgG levels and FEV1 decline was not statistically 
significant (P =  0.485). In another study of 20 patients with 
PAD, a clear correlation between higher IgG trough levels and 
preservation of FEV1 (R2 =  0.2688; P =  0.0281) was observed 
(117). A significant correlation between serum IgG trough level 
and FVC and FEV1 values was found also in 12 patients with 
hypogammaglobulinemia and ILD and led to the conclusion 
that the minimal target serum IgG level should be 5 g/L (118). 
Collectively, these studies suggest higher doses of IgG may be 
considered for patients showing deteriorating lung function; 
however, maximum recommended trough IgG levels have not 
been determined. The decline in FEV1 also appeared slower in 
patients who spent longer periods of time on antibiotics; however, 
the correlation was not significant (P = 0.1195) (117).
Based on these rates of decline in FEV1, we recommend at 
least annual PFT monitoring (including DLCO if available) for 
patients with PAD older than 5 years of age (117). Testing more 
frequently may be appropriate for those experiencing a more 
rapid decline of lung function (119).
Recently, several clinical trials employed a new technology, 
the multiple breath washout technique (MBW). MBW assesses 
the quality of ventilation, indicated by the lung clearance index 
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(LCI) during regular breathing. This method is not only less 
dependent on the cooperation of the patient, thus allowing use 
in children as young as age 4, but also appears more sensitive 
to minor changes at an early stage of lung disease and more 
meaningful in advanced disease, as shown in CF (120), primary 
ciliary dyskinesia (121), and non-CF bronchiectasis (122), in all 
of which LCI correlated better to the extent of bronchiectasis than 
FEV1. Finally, MBW appeared also more sensitive for assessing 
changes in lung disease in clinical trials with relatively short-term 
interventions. Inhalation of hypertonic saline in a small group 
(n = 20) of children with CF over a period of 4 weeks resulted in 
a significant improvement of LCI (treatment effect 1.16 ± 0.94), 
but not of spirometry parameters (123). However, to observe a 
significant change in FEV1 [% predicted] with this intervention, 
a sample size of 351 patients would have been required.
High-Resolution CT
Pulmonary functional tests have a low sensitivity to screen for 
pulmonary complications such as ILD and bronchiectasis (124) 
and, therefore, should be combined with imaging techniques. 
The sensitivity of HRCT for detection of pulmonary complica-
tions in patients with CVID is superior to both chest X-ray and 
PFTs (125), but the method is associated with higher costs and 
radiation doses. Radiation dose is a potential concern for patients 
with CVID, who in some cases may be more radiosensitive than 
healthy subjects (126–128), particularly where over time repeated 
imaging may be clinically necessary. For these patients, and espe-
cially for children, CT techniques that use lower radiation doses 
should be considered. Although low-dose computed tomography 
(LDCT) uses less ionizing radiation than conventional CT scans, 
the predictive effective doses used in LDCT of the lungs may still 
be 4–12 times greater than those used in conventional X-rays 
(129). A possibility to further reduce the radiation dose in lung CT 
scans would be to use the model-based iterative reconstruction 
(MBIR) technique for ultra-low-dose chest CT. MBIR provides 
an almost 80% reduction in radiation dose for chest CT without 
reducing sensitivity (130).
HCRT can be critical in the early diagnosis of airway abnormali-
ties (airway disease) and ILD, which cannot be differentiated by 
PFTs (131). In patients with CVID, HRCT revealed airway disease 
in 20% of pediatric patients and 30% of adults, and ILD in 15% of 
children and 34% of adults, respectively (124, 131). In the adult 
population, the presence of ILD correlated positively with autoim-
mune disease and markedly lower CD4+ T cell, naïve CD4+ T cell, 
and naïve and switched memory B-cell counts (124). Both airway 
disease and ILD are treatable diseases but differ in etiology and 
require different treatment. While high-dose IGRT may impact 
progression of airway disease in patients with CVID, ILD responds 
to immunosuppressive therapy. In pediatric CVID patients with 
ILD, nodules on HCRT disappeared following treatment with 
steroids, suggesting that early ILD may be reversible (131). As ILD 
appears to be asymptomatic during the initial stage, screening of 
all patients with CVID should facilitate early disease detection and 
enable early therapy which could be less aggressive (131).
There is a need for standardized HCRT scoring methods to 
facilitate efficient screening and follow-up for pulmonary com-
plications associated with CVID (131, 132). To aid the assessment 
of unrecognized lung disease progression in these patients, 
the scoring system should be based on abnormalities specific 
for PAD, rather than adapted from other diseases such as CF. 
A scoring method was developed in a cohort of 54 children with 
stable CVID or CVID-like disorders (132). In this pediatric study 
population, lung abnormalities were common (found in 85–95% of 
patients), although the overall extent and severity of abnormalities 
were mild. Bronchial pathology was the most common pathology, 
observed in up to half and one-third of the patients with bron-
chial wall thickening and bronchiectasis, respectively. However, 
interstitial pathology and ventilation pathology were described 
as affecting a third (air trapping) and a quarter (nodules) of the 
patients. The latter was effectively treated with corticosteroids in 
some cases. The Chest CT in Antibody Deficiency Group is cur-
rently developing a quantitative scoring system that can be used as 
a validated tool in multicenter studies and could help to endorse 
uniform documentation of chest CT scans (133).
Magnetic Resonance imaging (MRi) with 
Diffusion weighted imaging (Dwi)
Magnetic resonance imaging with DWI offers a radiation-free 
alternative to the HRCT scan. MRI has been shown to be non-
inferior to HRCT in identifying bronchial and parenchymal 
abnormalities, although HCRT had a higher capacity in identify-
ing peripheral airway abnormalities (134). PFT alterations cor-
related well with MRI bronchial abnormalities, but not with MRI 
parenchymal scores (134). The implementation of DWI facilitates 
the acquisition of information about the microstructure of the 
tissue and may enable detection of areas of inflammation and sub-
clinical infection in lung parenchyma (134). However, although 
promising, MRI DWI is technically demanding, requires an 
expert radiologist, and possibly necessitates sedation in children.
inflammatory and Clinical Biomarkers
To determine the need of anti-inflammatory drugs as adjunctive 
therapy in PAD, reliable biomarkers are required. Potentially 
useful biomarkers of infection risk are the presence of sinusitis, 
low IgG trough levels, low IgA, and bronchiectasis. Similarly, the 
following symptoms could be valuable as biomarkers of non-
infectious inflammation: low class-switched memory B-cells, 
autoimmunity, low T  cells and naïve T  cells, splenomegaly, 
lymphadenopathy, and potentially elevated IgM and beta 2 
microglobulin (100). However, data on biomarkers in peripheral 
blood are not available, except for low endogenous plasma IgG 
concentrations measured prior to IGRT and a deficiency of 
class-switched memory B cells (24, 135, 136). IgM levels are not 
always low in patients with CVID, but they were reported to be 
lower in patients experiencing recurrent infections compared 
with those with fewer infections (24). Splenomegaly can be a 
biomarker for GLILD, given the multi-systemic nature of the 
disease (81). Abnormalities in the T-cell population found in 
BALF, such as a low CD4/CD8 ratio, can be associated with poor 
functional outcomes including FEV1 and FVC (137). However, 
bronchoalveolar lavage for T-cell assessment is an invasive tech-
nique and thus it is usually used only in patients with severe 
disease. Other potential inflammatory markers in spontaneously 
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expectorated (138) or induced (139) sputum, including cellular 
content, cytokines, reactive oxygen metabolites, and bacterial 
density (140) have been evaluated in various conditions including 
CVID, yet before they can become a reality in this setting, further 
studies are needed (43). Likewise, there are no reliable data of the 
usefulness of beta 2 microglobulin in patients with PAD.
Microbiological surveillance of patients with PAD is of great 
clinical importance. Although it is currently unclear how many 
episodes of bacterial infection in PAD are preceded by viral 
infections of the upper airway (2), appropriate microbiological 
surveillance may help understand and prevent infection progres-
sion. The surveillance protocol in patients with PAD may include 
regular chest HRCT and PFTs (including DLCO and possibly 
LCI) or MRI with DWI as an alternative to CT with optional 
sputum analysis and molecular detection with polymerase chain 
reaction (3, 4).
CONCLUSiON
Pulmonary morbidity in patients with PAD advances despite 
apparently adequate IGRT. New preventive and therapeutic 
approaches are urgently needed. Clinical trials to evaluate these 
approaches will rely on new ways of assessing and documenting 
lung disease. Optimal pulmonary management must encompass 
the upper airway, the “gateway to the lung.” Non-infectious com-
plications such as non-infectious lymphoproliferation, where 
GLILD represents the pulmonary component, contribute sub-
stantially to morbidity in these patients, and requires specific 
treatment. Regular assessment of the structural and functional 
condition of the lung as well as an improved understanding of 
subclinical recurrent infections will, we hope, inform therapeutic 
decisions aiming to reduce lung damage.
KeY TAKe-HOMe MeSSAGeS
• Lung disease, both infectious and non-infectious, progresses 
despite IGRT
• Characteristics making lung disease more likely include exist-
ing inflammatory/autoimmune disease, lymphadenopathy, 
splenomegaly, low counts of class-switched memory B  cells, 
and CD4+ T cells
• Improved molecular characterization of gene defects has led to 
identification of several monogenic defects which appear to be 
associated with granulomatous-lymphocytic ILD (mutations 
in TACI, CTLA-4 haploinsufficiency, or LRBA deficiency, 
mutations in XIAP, hypomorphic RAG1 mutations, and 
KMT2D mutations)
• A better understanding of the natural history and pathogenesis 
of ILD in PAD is needed
• Early diagnosis may allow interventions to prevent or slow end 
organ damage
• New and improved PFT modalities now exist and warrant 
further study for utility in PAD
• Low-dose CT scans and radiation-free alternative scans offer 
an improved safety profile in PAD
• Standardized multi-center documentation of chest CT scans 
is one of the tools for providing better data on natural history 
and interventions
• Optimal pulmonary management of patients with PAD must 
encompass the upper airway, which serves as the “the gateway” 
to the lungs
• There are few clinical studies evaluating potential treatments 
of lung disease in PAD
• Early targeted intervention may reduce the burden of steroids 
currently employed, which are used over long periods of time 
with only partial efficacy
• New therapies are needed to relieve the burden of viral 
infections
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